BioSyent (CVE:RX) Reaches New 52-Week High – Here’s Why

BioSyent Inc. (CVE:RX – Get Free Report) shares hit a new 52-week high on Thursday. The company traded as high as C$17.41 and last traded at C$17.37, with a volume of 3,329 shares trading hands. The stock had previously closed at C$17.15.

BioSyent Stock Up 2.1%

The company has a debt-to-equity ratio of 6.85, a current ratio of 2.07 and a quick ratio of 6.91. The company has a market cap of C$198.81 million, a price-to-earnings ratio of 20.73 and a beta of 1.08. The firm’s 50 day simple moving average is C$16.51 and its 200-day simple moving average is C$15.06.

Insider Buying and Selling at BioSyent

In other news, Director Seyed Ahmad Ashrafi sold 2,900 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of C$16.55, for a total value of C$47,995.00. Following the completion of the sale, the director directly owned 21,461 shares of the company’s stock, valued at approximately C$355,179.55. The trade was a 11.90% decrease in their position. Over the last ninety days, insiders sold 7,251 shares of company stock valued at $118,207. 33.65% of the stock is currently owned by insiders.

BioSyent Company Profile

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.

Featured Articles

Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.